Evidence map›Paper›PMID 39011060›Full record

ArticleFrontiers in toxicology2024

Evaluation of the immunotoxicity potential of nanomaterials using THP-1 cells.

Asuka Nishida, Yuka Sawada, Rion Arai, Naoki Ishibashi, Miho Suzuo, Akiko Ohno, Takao Ashikaga, Kazutoshi Iijima

Abstract read
In one paragraph

Article in Frontiers in toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Asuka NishidaGraduate School of Engineering Science, Yokohama National University, Yokohama, Japan.
Yuka SawadaGraduate School of Engineering Science, Yokohama National University, Yokohama, Japan.
Rion AraiGraduate School of Engineering Science, Yokohama National University, Yokohama, Japan.
Naoki IshibashiCollege of Engineering Science, Yokohama National University, Yokohama, Japan.
Miho SuzuoCollege of Engineering Science, Yokohama National University, Yokohama, Japan.
Akiko OhnoDivision of Risk Assessment, National Institute of Health Sciences, Kawasaki, Japan.
Takao AshikagaDivision of Risk Assessment, National Institute of Health Sciences, Kawasaki, Japan.
Kazutoshi IijimaFaculty of Engineering, Yokohama National University, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the expansion of nanomaterials (NMs) usage, concerns about their toxicity are increasing, and the wide variety of NMs makes it difficult to assess their toxicity. Therefore, the development of a high-throughput, accurate, and certified method to evaluate the immunotoxicity of NMs is required. In this study, we assessed the immunotoxicity potential of various NMs, such as nanoparticles of silver, silica, and titanium dioxide, using the human Cell Line Activation Test (h-CLAT) at the cellular level. After exposure to silver nanoparticle dispersions, the expression levels of CD86 and CD54 increased, suggesting the activation of antigen-presenting cells (APCs) by silver nanoparticles. Quantification of silver ions eluted from silver nanoparticles and the activation of APCs by silver ions suggested that it was due to the release of silver ions. Silica nanoparticles also increased the expression of CD86 and/or CD54, and their activation ability correlated with the synthesis methods and hydrodynamic diameters. The ability of titanium dioxide to activate APCs differed depending on the crystal type and hydrodynamic diameter. These results suggest a potential method to evaluate the immunotoxicity potential of various NMs based on their ability to activate APCs using human monocytic THP-1 cells. This method will be valuable in assessing the immunotoxicity potential and elucidating the immunotoxic mechanisms of NMs.

Indexed as

antigen-presenting cellsimmunotoxicitynanomaterialssilicasilverTHP-1 cellstitanium dioxide

Identifiers

PMID39011060
PMCPMC11247007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.